GENMAB Inactive Instrument
Genmab Stock Nasdaq Copenhagen
Equities
DK0010272202
Biotechnology & Medical Research
|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,952 DKK | +60.37% |
|
+4.14% | +14.24% |
| Apr. 16 | Genmab, Johnson & Johnson Logs Higher Q1 Sales for Blood Cancer Drug | MT |
| Apr. 16 | Genmab A/S Announces DARZALEX Sales Results for the First Quarter of 2024 | CI |
| Sales 2024 * | 19.66B 2.83B | Sales 2025 * | 23.51B 3.38B | Capitalization | 128B 18.38B |
|---|---|---|---|---|---|
| Net income 2024 * | 5.11B 734M | Net income 2025 * | 6.76B 971M | EV / Sales 2024 * | 5.15 x |
| Net cash position 2024 * | 26.57B 3.82B | Net cash position 2025 * | 33.5B 4.81B | EV / Sales 2025 * | 4.02 x |
| P/E ratio 2024 * |
25.3
x | P/E ratio 2025 * |
19.4
x | Employees | - |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.87% |
More Fundamentals
* Assessed data
More news
Latest transcript on Genmab
More recommendations
More press releases
More news
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 63 | 98-12-31 | |
Anthony Pagano
DFI | Director of Finance/CFO | 46 | 06-12-31 |
Anthony Mancini
COO | Chief Operating Officer | 53 | 20-03-22 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Deirdre Connelly
CHM | Chairman | 63 | 16-12-31 |
Anders Pedersen
BRD | Director/Board Member | 73 | 03-10-31 |
Rolf K. Hoffmann
BRD | Director/Board Member | 63 | 15-12-31 |
Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows:
- royalties (83.2%);
- income from research and development (12.4%);
- other (4.4%): primarily income from partnership agreement.
At the end of 2023, the group had a portfolio of more than 20 products in clinical development phase and 20 in preclinical development phase.
Denmark accounts for all net sales.
Calendar
2024-05-02
- Q1 2024 Earnings Release
Related indices
| 1st Jan change | Capi. | |
|---|---|---|
| -1.51% | 104B | |
| +3.22% | 97.42B | |
| +1.69% | 22.2B | |
| -16.53% | 21.23B | |
| -42.33% | 16.35B | |
| -20.09% | 15.06B | |
| +5.47% | 13.98B | |
| +28.85% | 11.66B | |
| -24.93% | 8.22B |
